Josephson Colin B, Howlett Jonathan G, Jackson Simon D, Finley John, Kells Catherine M
Department of Medicine, Dalhousie University, Halifax, Canada.
Can J Cardiol. 2006 Jul;22(9):769-72. doi: 10.1016/s0828-282x(06)70293-8.
Patients with atrial switch (Mustard or Senning) repair of D-transposition of the great arteries (D-TGA) are at increased risk for atrial arrhythmias, systemic right ventricular (RV) dysfunction and late mortality.
To evaluate case series from a single-centre experience with beta-blocker use in adult, post atrial switch, simple D-TGA patients.
The Adult Congenital Heart Disease Clinic (Halifax, Nova Scotia) database was used to identify patients with post atrial switch, simple D-TGA. Treatment effect of beta-blockade was evaluated.
Eight patients were treated with beta-blockers for systemic RV dysfunction (n=2), arrhythmia (n=2) or both (n=4). Median follow-up was three years, at which time seven of eight patients were still on beta-blockade. Of those patients with complete data, two of five had improved systemic ventricular dysfunction, two of four had improved tricuspid regurgitation and four of six had improved functional capacity, as determined by history or exercise testing. Beta-blockade was well tolerated in seven of eight patients without any significant clinical deterioration.
Beta-blockade was used infrequently in patients with a prior Mustard procedure. When beta-blockade was prescribed to patients with a prior atrial switch procedure, the drugs were well tolerated and were associated with trends toward improved symptoms, less tricuspid regurgitation and improved functional status in patients with reduced systemic RV function. These data support the need for a randomized trial of beta-blockade in patients with a previous Mustard or Senning operation and RV dysfunction.
接受心房调转术(Mustard或Senning术)治疗大动脉转位(D-TGA)的患者发生房性心律失常、体循环右心室(RV)功能障碍及晚期死亡的风险增加。
评估单中心对成年、心房调转术后单纯D-TGA患者使用β受体阻滞剂的病例系列。
利用成人先天性心脏病诊所(新斯科舍省哈利法克斯)数据库识别心房调转术后单纯D-TGA患者。评估β受体阻滞剂的治疗效果。
8例患者因体循环RV功能障碍(n=2)、心律失常(n=2)或两者兼具(n=4)接受β受体阻滞剂治疗。中位随访时间为3年,此时8例患者中有7例仍在使用β受体阻滞剂。在有完整数据的患者中,根据病史或运动试验判断,5例中有2例体循环心室功能改善,4例中有2例三尖瓣反流改善,6例中有4例功能能力改善。8例患者中有7例对β受体阻滞剂耐受性良好,无任何明显临床恶化。
既往接受Mustard手术的患者很少使用β受体阻滞剂。当对既往接受心房调转术的患者使用β受体阻滞剂时,药物耐受性良好,且与体循环RV功能降低患者症状改善、三尖瓣反流减少及功能状态改善的趋势相关。这些数据支持对既往接受Mustard或Senning手术且存在RV功能障碍的患者进行β受体阻滞剂随机试验的必要性。